Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Daniel T, Mytych"'
Autor:
Mark A. Kroenke, Marta Starcevic Manning, Christina L. Zuch de Zafra, Xinwen Zhang, Kevin D. Cook, Michael Archer, Martijn P. Lolkema, Jin Wang, Sarah Hoofring, Gurleen Saini, Famke Aeffner, Elizabeth Ahern, Elena Garralda Cabanas, Ramaswamy Govindan, Mun Hui, Shalini Gupta, Daniel T. Mytych
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/72f24fcbd43448008d13f236f8a3523a
Autor:
Mark A. Kroenke, Marta Starcevic Manning, Christina L. Zuch de Zafra, Xinwen Zhang, Kevin D. Cook, Michael Archer, Martijn P. Lolkema, Jin Wang, Sarah Hoofring, Gurleen Saini, Famke Aeffner, Elizabeth Ahern, Elena Garralda Cabanas, Ramaswamy Govindan, Mun Hui, Shalini Gupta, Daniel T. Mytych
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
AMG 256 is a bi-specific, heteroimmunoglobulin molecule with an anti-PD-1 antibody domain and a single IL-21 mutein domain on the C-terminus. Nonclinical studies in cynomolgus monkeys revealed that AMG 256 administration led to the development of imm
Externí odkaz:
https://doaj.org/article/9a833fe6e7534142a8fff16ef8164fb5
Autor:
Hweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, Bin Wu, Christian Brandl, Christian Webhofer, Mason McComb, Sabine Wittemer-Rump, Gökben Koca, Sabine Stienen, Ralf C. Bargou, Horst-Dieter Hummel, Wolfgang Loidl, Carsten Grüllich, Tobias Eggert, Ben Tran, Daniel T. Mytych
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionIn oncology, anti-drug antibody (ADA) development that significantly curtails response durability has not historically risen to a level of concern. The relevance and attention ascribed to ADAs in oncology clinical studies have therefore b
Externí odkaz:
https://doaj.org/article/212fa5cf8e9f4350b4b25e8f215a32d7
Autor:
Hweixian L Penny, Yanchen Zhou, Mark A Kroenke, Bianca Bautista, Kelly Hainline, Lynette S Chea, Jane Parnes, Daniel T Mytych
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/d4195547369b45f4a63d1c15bf26da04
Autor:
Mark A. Kroenke, Troy E. Barger, Jenny Hu, Mieke Jill Miller, Kevin Kalenian, Lidong He, Hailing Hsu, Yessenia Bartley, Vincent Fung-Sing Chow, Marcia Cristina Teixeira dos Santos, Barbara A. Sullivan, Laurence E. Cheng, Jane R. Parnes, Rupa Padaki, Scott Kuhns, Daniel T. Mytych
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
AMG 966 is a bi-specific, heteroimmunoglobulin molecule that binds both tumor necrosis factor alpha (TNFα) and TNF-like ligand 1A (TL1A). In a first-in-human clinical study in healthy volunteers, AMG 966 elicited anti-drug antibodies (ADA) in 53 of
Externí odkaz:
https://doaj.org/article/bb8a16473b134591babbad71b1979d57
Autor:
Yanchen Zhou, Hweixian L Penny, Mark A Kroenke, Bianca Bautista, Kelly Hainline, Lynette S Chea, Jane Parnes, Daniel T Mytych
Publikováno v:
Journal for immunotherapy of cancer. 10(4)
With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering the clinic, recent data highlight immunogenicity as an emerging challenge in the development of such novel biologics. This review focuses on the immunogenici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9fe04ab4045cd99e548e90a3b0c193
https://pubmed.ncbi.nlm.nih.gov/35444060
https://pubmed.ncbi.nlm.nih.gov/35444060
Publikováno v:
European Journal of Haematology. 105:66-74
Objectives ABP 959 is a proposed biosimilar to eculizumab, a monoclonal antibody targeting the human C5 complement protein. The objective of this randomized, double-blind, three-arm, study was to demonstrate pharmacokinetic (PK) and pharmacodynamic (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27f6273fe015a98275e0d5bbe40a456d
https://doi.org/10.1111/ejh.13411
https://doi.org/10.1111/ejh.13411
Autor:
Joseph K. Park, Troy E. Barger, June Kim, David J. Kuter, Vibha Jawa, Andy Boshier, Daniel T. Mytych
Publikováno v:
British Journal of Haematology
Summary Antibodies to first‐generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second‐generation TPO receptor agonist romiplostim, having no s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4242a0d19611b4c500a82f239b3cc500
https://pubmed.ncbi.nlm.nih.gov/32311075
https://pubmed.ncbi.nlm.nih.gov/32311075
Publikováno v:
European Journal of Haematology
Objectives ABP 959 is a proposed biosimilar to eculizumab, a monoclonal antibody targeting the human C5 complement protein. The objective of this randomized, double‐blind, three‐arm, study was to demonstrate pharmacokinetic (PK) and pharmacodynam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3230719430360c94d6188fdc48d347a6
https://pubmed.ncbi.nlm.nih.gov/32196749
https://pubmed.ncbi.nlm.nih.gov/32196749
Publikováno v:
The AAPS journal. 22(3)
This document highlights some relevant factors in the assessment of immunogenicity risk of fusion protein therapeutics. Our aim is to highlight specific risks associated with this type of molecule, while also aligning with general risk assessment fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1a4aae58e475093e45fc33d576fb438
https://pubmed.ncbi.nlm.nih.gov/32246297
https://pubmed.ncbi.nlm.nih.gov/32246297